Table 1.
Comparison between both groups regarding demographic and clinical characteristics
| No Ivabradine (n = 656) | Ivabradine (n = 342) | P-value | |
|---|---|---|---|
| Age (years) | 61.2 ± 14.4 | 61.6 ± 13.9 | 0.67 |
| Male Sex | 490 (74.7) | 255 (74.6) | 0.97 |
| Ischemic etiology | 509 (77.6) | 265 (77.5) | 0.97 |
| Hypertension | 492 (75) | 247 (72.2) | 0.34 |
| Diabetes Mellitus | 321 (48.9) | 177 (51.8) | 0.38 |
| Smoking | 433 (66) | 209 (61.1) | 0.13 |
| Dyslipidemia | 118 (18) | 55 (16.1) | 0.45 |
| Ejection fraction (%) | 46 ± 12 | 47 ± 13 | 0.23 |
| Hemoglobin (g/dl) | 12.8 ± 1.4 | 12.7 ± 1.5 | 0.3 |
| Serum creatinine (mg/dl) | 0.71 ± 1.1 | 0.82 ± 0.9 | 0.11 |
| Platelet count (103/ml-3) | 259 ± 113 | 265 ± 99 | 0.41 |
| ACEIs/ARBs | 429 (65.4) | 225 (65.8) | 0.9 |
| ARNI | 190 (29) | 93 (27.2) | 0.55 |
| MRA | 499 (76.1) | 253 (74) | 0.47 |
| Baseline Heart rate (BPM) | 90 ± 12 | 87 ± 15 | 0.0006* |
Data are number (%) or mean ± S.D. ACEIs: Angiotensin Converting Enzymes Inhibitors, ARBs: Angiotensin Receptor Blockers, ARNI: Angiotensin Receptor Neprilysin Inhibitor, MRA: Mineralocorticoid Receptor Antagonist, BPM: beats per minute.
*
Significant P-value < 0.05.